Tumour necrosis factor neutralization in MS: A cautionary tale

International MS Journal

Volumn 17, Issue 2, 2011, Pages 63-68

  Arnason, B G W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CIPROFLOXACIN; GADOLINIUM; INTERLEUKIN 10; LENERCEPT; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; HUMAN; LIMB WEAKNESS; MULTIPLE SCLEROSIS; MUSCLE SPASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SENSORY DYSFUNCTION; VERTIGO; VISUAL IMPAIRMENT; ANIMAL; DOUBLE BLIND PROCEDURE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ANIMALS; DOUBLE-BLIND METHOD; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959737342     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170:607-612.
2. Bitsch A, Kuhlmann T, DaCosta C, Bunkowski S, Polak T, Bruck W. Tumor necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 2000; 29:366-375.
3. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23:339-346.
4. Drojdahl N, Fenger C, Nielsen HH, Owens T, Finsen B. Dynamics of oligodendrocyte responses to anterograde axonal (Wallerian) and terminal degeneration in normal and TNF-transgenic mice. J Neurosci Res 2004; 75:203-217.
5. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokine: a primary role for tumor necrosis factor. J Immunol 1990; 144:129-135.
6. Baune BT, Wiede F, Braun A, Golledge J, Aroit V, Koerner H. Cognitive dysfunction in mice deficient for TNF-and its receptors. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1056-1064.
7. Aloe L, Properzi F, Probert L, Akassoglou K, Kassiotis G, Micera A, Fiore M. Learning abilities, NGF and BDNF brain levels in two lines of TNF-a transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Res 1999; 840:125-137.
8. Brosnan CF, Litwak MS, Schroeder CE, Selmaj K, Raine CS Arezzo JC. Preliminary studies of cytokine-induced functional effects on the visual pathways in the rabbit. J Neuroimmunol 1989; 25: 227-239.
9. Hollifield RD, Harbige LS, Pham-Dinh D, Sharief MK. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 2003; 36: 133-141.
10. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78:318-323.
11. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Brooks A, Luer W, Helwig A, Poser S. Tumor necrosis factor alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995; 37:82-88.
12. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172:1193-1200.
13. Selmaj K, Papierz W, Glabinski A, Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995; 56:135-141
14. Martin D, Near SL, Bendele A, Russell DA. Inhibition of tumor necrosis factor is protective against neurologic dysfunction after active immunization of Lewis rats with myelin basic protein. Exp Neurol 1995; 131: 221-228.
15. Selmaj KW, Raine CS. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995; 45 (Suppl 6):S44-S49.
16. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24: 2040-2048.
17. Hovelmeyer N, Hao Z, Kranidioti K, Kassiotis G, Buch T, Frommer F, et al. Apoptososis of oligodendrocytes via Fas and TNF-RI is a key event in the induction of experimental autoimmune encephalomyelitis. J Immunol 2005; 175:5875-5884.
18. Kuroda Y, Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 1991; 34:159-164.
19. Crisi GM, Santambrogio L, Hochwald GM, Smith SR, Carlino JA, Thorbecke GJ. Staphylococcal enterotoxin B and tumor necrosis factor-a-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor- and interleukin-10. Eur J Immunol 1995; 25:3035-3040.
20. Powell MB, Mitchell D, Lederman J, Buckmeier J, Zamvil SS, Graham M, et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990; 2:539-544.
21. Klinkert WEF, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H. TNF-a receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997; 72:163-168.
22. The Lenercept Multiple Study Group and the University of British Columbia MS/MRI Analysis Group.TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53:457-465.
23. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann F W, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531-1534.
24. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occuring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44:2862-2869.
25. Frei K, Eugster H-P, Bopst M, Constantinescu CS, Lavi E, Fontana A. Tumor necrosis factor a and lymphotoxin are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997; 185:2177-2182.
26. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapur J. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4:78-83.
27. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997; 186:1585-1590.
28. Kassiotis G, Pasparakis M, Kollias G, Probert L. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur J Immunol 1999; 29:774-780.
29. Myers LW, Ellison GW, Merrill JE, El-Hajjar A, Pierre B, Hijazin M, et al. Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase. Neurology 1998; 51: 1483-1486.
30. Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection 2005; 33 (suppl 2): 55-70.
31. Purswani MU, Eckert SJ, Arora HK, Noel GJ. Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. J Antimicrob Chemother 2002; 50:51-58.
32. Ogino H, Fujii M, Ono M, Maezawa K, Hori S, Kizu J. In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced pro-inflammatotry cytokine production. J Infect Chemother 2009; 15:168-173.
33. Gogos CA, Skoutelis A, Lekkou A, Drosou E, Starakis I, Marangos MN, Bassaris HP. Comparative effects of ciprofloxacin and ceftazidine on cytokine production in patients with severe sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 2004; 48:2793-2798.
34. Ziegeler S, Raddatz A, Hoff G, Buchinger H, Bauer I, Stockhausen A, et al. Antibiotics modulate the stimulated cytokine response to endotoxin in a human ex vivo, in vitro model. Acta Anaesthesiol Scand 2006; 50:1103-1110.
35. Wanidworanun C, Strober W. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 1993; 151: 6853-6861.